Sector News

Alexion Names David Hallal COO

September 18, 2014
Life sciences
(RTTNews) – Alexion Pharmaceuticals, Inc., whose durg Soliris treats two rare diseases, Wednesday said it is promoting David Hallal to the newly created position of chief operating officer.
 
Hallal, who joined the company in 2006, was previously its executive vice president and chief commercial officer. He led the launch of Soliris. Before Alexion, he was worked at Biogen Idec and Amgen.
 
The company also promoted two members of the management to executive vice president from vice president: Chief Human Resources Officer Clair Carmichael ; and General Counsel John Moriarty.
 
The company further said it appointed Edward Miller to the nearly created position of Senior Vice President and Chief Compliance Officer.
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”